Prothena (PRTA) Reaches New 12-Month Low at $35.55

Shares of Prothena Corporation PLC (NASDAQ:PRTA) hit a new 52-week low during mid-day trading on Monday . The stock traded as low as $35.55 and last traded at $38.54, with a volume of 728500 shares trading hands. The stock had previously closed at $36.59.

Several brokerages have issued reports on PRTA. ValuEngine cut Prothena from a “hold” rating to a “sell” rating in a report on Friday, December 15th. Oppenheimer set a $70.00 target price on Prothena and gave the company a “buy” rating in a report on Monday, December 4th. Wedbush cut Prothena from an “outperform” rating to a “neutral” rating and dropped their target price for the company from $75.00 to $55.00 in a report on Monday, November 20th. Deutsche Bank set a $73.00 target price on Prothena and gave the company a “buy” rating in a report on Monday, October 23rd. Finally, Jefferies Group restated a “buy” rating and issued a $100.00 target price on shares of Prothena in a report on Monday, October 2nd. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and thirteen have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and a consensus price target of $76.75.

Prothena (NASDAQ:PRTA) last announced its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.37) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.41) by $0.04. Prothena had a negative return on equity of 34.40% and a negative net margin of 562.19%. The business had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.28 million. During the same quarter in the prior year, the company posted ($1.26) EPS. The company’s quarterly revenue was down 33.6% on a year-over-year basis. equities research analysts forecast that Prothena Corporation PLC will post -4.27 earnings per share for the current year.

In other news, insider Tara Nickerson sold 17,500 shares of the company’s stock in a transaction on Monday, September 25th. The stock was sold at an average price of $63.60, for a total value of $1,113,000.00. Following the transaction, the insider now owns 19,500 shares of the company’s stock, valued at approximately $1,240,200. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director Christopher S. Henney sold 900 shares of the company’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $70.00, for a total value of $63,000.00. Following the completion of the transaction, the director now directly owns 900 shares in the company, valued at approximately $63,000. The disclosure for this sale can be found here. In the last ninety days, insiders sold 29,424 shares of company stock worth $1,922,787. Corporate insiders own 3.10% of the company’s stock.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of Montreal Can lifted its stake in Prothena by 6.7% during the 2nd quarter. Bank of Montreal Can now owns 1,858 shares of the biotechnology company’s stock worth $100,000 after acquiring an additional 117 shares in the last quarter. Quantbot Technologies LP lifted its stake in Prothena by 672.7% during the 2nd quarter. Quantbot Technologies LP now owns 1,870 shares of the biotechnology company’s stock worth $101,000 after acquiring an additional 1,628 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in Prothena by 187.5% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,375 shares of the biotechnology company’s stock worth $129,000 after acquiring an additional 1,549 shares in the last quarter. Strs Ohio lifted its stake in Prothena by 69.2% during the 3rd quarter. Strs Ohio now owns 2,200 shares of the biotechnology company’s stock worth $142,000 after acquiring an additional 900 shares in the last quarter. Finally, Fieldpoint Private Securities LLC acquired a new position in Prothena during the 3rd quarter worth about $162,000.

COPYRIGHT VIOLATION NOTICE: This report was first posted by Sports Perspectives and is the property of of Sports Perspectives. If you are accessing this report on another publication, it was copied illegally and reposted in violation of U.S. & international copyright and trademark laws. The legal version of this report can be read at https://sportsperspectives.com/2017/12/20/prothena-prta-reaches-new-12-month-low-at-35-55.html.

About Prothena

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply